Previous close | 0.4400 |
Open | 0.3800 |
Bid | 0.2700 |
Ask | 0.6200 |
Strike | 100.00 |
Expiry date | 2024-10-18 |
Day's range | 0.3800 - 0.4400 |
Contract range | N/A |
Volume | |
Open interest | 6.68k |
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma